Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 5/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681101 | 0.92 | KDM1A (0.53) | VEGFAEGLN1KDM1AHRH3CHRM2 | |
| SCHEMBL18608789 | 0.89 | MEN1 (0.58) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL2363123 | 0.89 | VEGFA (0.56) | VEGFAEGLN1KDM1AHRH3CHRM2 | |
| SCHEMBL2858333 | 0.89 | TP53 (0.58) | VEGFAEGLN1KDM1AHRH3CHRM2 | |
| SCHEMBL5536182 | 0.89 | VEGFA (0.68) | VEGFAEGLN1KDM1ACHRM2CHRM4 | |
| SCHEMBL4938599 | 0.89 | VEGFA (0.56) | VEGFAEGLN1KDM1AHRH3CHRM2 | |
| SCHEMBL23250104 | 0.87 | VEGFA (0.55) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL1433245 | 0.87 | POLB (0.58) | VEGFAEGLN1HRH3CHRM2CHRM4 | |
| SCHEMBL20910175 | 0.87 | VEGFA (0.55) | VEGFAEGLN1KDM1AHRH3CHRM2 | |
| SCHEMBL21198803 | 0.87 | VEGFA (0.55) | VEGFAEGLN1HRH3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2021-01-07 | — | — | US | disclosed |
| WO-2019118830-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-9587035-B2 | Assay for benzylpiperazine and metabolites | RANDOX LABORATORIES LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2679241-B1 | Assay for benzylpiperazines and metabolites | RANDOX LAB LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| WO-2014072903-A1 | NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
| US-4247549-A | Piperazine-1-carboxylic acid esters possessing antidepressant or analgesic activity | ICI AMERICAS INC. (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | VEGFA 2122/4885EGLN1 1530/4885KDM1A 4496/4885 |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | APP, BACE1, IAPP | VEGFA 2255/4885EGLN1 3671/4885KDM1A 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.